Management of locally advanced basal cell carcinoma treated with sonidegib: The experience of an Italian reference hospital

Conforti, Claudio; Giuffrida, Roberta; Meo, Nicola di; Zalaudek, Iris

doi:10.1111/dth.14511

Cited by 6 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 3 , 4 Sonidegib, is a selective hedgehog pathway inhibitor (HHI) approved in 2015 for patients with laBCC that are ineligible for surgery and/or radiation therapy. 5 To date, clinical trials and case reports regarding its efficacy and tolerability, also during COVID‐19 pandemic period, 6 have already been reported 7 , 8 ; the aim of this study is to report the efficacy of sonidegib in treating laBCCs localized in critical structures as the head–neck region, highlighting also the cosmetic results reported in patients achieving the complete remission of the tumor. This retrospective analysis included patients with head–neck laBCCs treated with sonidegib at the Non‐Melanoma Skin Cancer Unit of the University of Federico II in Naples from February 2020 to December 2020.…”

Section: Tablementioning

confidence: 99%

Systemic hedgehog inhibitors to treat locally advanced basal cell carcinomas of the head–neck region: A retrospective study

Villani

Costa

Fabbrocini

et al. 2021

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

Section: Tablementioning

confidence: 99%

Systemic hedgehog inhibitors to treat locally advanced basal cell carcinomas of the head–neck region: A retrospective study

Villani

Costa

Fabbrocini

et al. 2021

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…Telemedicine can be a useful adjunct tool for patients who are able to provide digital photos of their lesions of suitable standard for comparison with previous images. 29 …”

Section: Case Reportsmentioning

confidence: 99%

Experience with sonidegib in patients with advanced basal cell carcinoma: case reports

Puig¹,

Serra‐Guillén²,

Pérez‐Pastor³

et al. 2022

DIC

View full text Add to dashboard Cite

Sonidegib is a Hedgehog signalling pathway inhibitor approved for use in patients with advanced basal cell carcinoma (BCC) not eligible for surgery or radiotherapy. This report describes clinical experience with sonidegib in two patients with locally advanced BCC (one with a tumour adjacent to the right eye and the other with a tumour associated with the left ear) and in one patient with Gorlin syndrome. Two of the patients had recurrent and intractable tumours. Treatment with sonidegib 200 mg/day led to remission in both patients with locally advanced BCC within 7 months and to a reduction in the size and number of lesions after 4 months in the patient with Gorlin syndrome. Adverse effects reported in these patients were cramps, alopecia, ageusia and weight loss, all of which were mild and consistent with the known toxicity profile for sonidegib. Sonidegib has an important role to play in the effective treatment of challenging cases of advanced BCC. In parallel, a need remains to improve management protocols for patients with advanced BCC, particularly through earlier intervention and a multidisciplinary team approach.

show abstract

Neoadjuvant Therapy for Non-melanoma Skin Cancer: Updated Therapeutic Approaches for Basal, Squamous, and Merkel Cell Carcinoma

Zelin

Zalaudek

Agozzino

et al. 2021

Curr. Treat. Options in Oncol.

Self Cite

View full text Add to dashboard Cite

Opinion statementRecently introduced systemic therapies for locally advanced and metastatic non-melanoma skin cancers (NMSCs) are paving the way for neoadjuvant approach. Although none of the therapeutic options has currently gained indication in this setting, neoadjuvant approach for NMSCs is an open field and we are likely to see huge developments in the near future. Targeted therapy with sonic hedgehog pathway inhibitors is very effective in locally advanced or multiple basal cell carcinomas while immunotherapy with immune checkpoint inhibitors appears to be promising for advanced cutaneous squamous cell carcinoma and Merkel cell carcinoma. To date, targeted therapy and immunotherapy represent the frontiers in NMSC therapeutic management and, according to recent studies, good results can be achieved.

show abstract

Management of locally advanced basal cell carcinoma treated with sonidegib: The experience of an Italian reference hospital

Cited by 6 publications

References 8 publications

Systemic hedgehog inhibitors to treat locally advanced basal cell carcinomas of the head–neck region: A retrospective study

Systemic hedgehog inhibitors to treat locally advanced basal cell carcinomas of the head–neck region: A retrospective study

Experience with sonidegib in patients with advanced basal cell carcinoma: case reports

Neoadjuvant Therapy for Non-melanoma Skin Cancer: Updated Therapeutic Approaches for Basal, Squamous, and Merkel Cell Carcinoma

Contact Info

Product

Resources

About